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suggesting that some RET-translocated lung adenocar-
cinomas respond to RET-inhibitor therapy. The role of 
RET-targeted therapy in RET-translocated lung adenocar-
cinomas requires further validation in clinical trial studies 
with novel RET inhibitors.
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Erratum
Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma: Erratum
The affiliation for the authors of the article beginning on page 1329 of the October 2013 issue was incorrectly listed as Shanghai Thoracic Hospital. The 
correct affiliation is Shanghai Chest Hospital.
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